title: [Not Available].
abstract: In order to evaluate the attractiveness of France for conducting international clinical trials, a survey is performed every two years among pharmaceutical companies that are based in France or have aﬃliates in France. Nineteen companies (61.9 % of the French market) have participated in the current survey which included 385 international phase II and III clinical studies, 77 countries, 29,708 centres and 312,835 patients (included in 2006/2007). France (400 patients/million inhabitants) ranked among the best European recruiters in second position behind Scandinavia. Since 2006, France has improved administrative processes and reduced deadlines for hospital contracts. Protocols are now to be given the go-ahead by French Authorities (Afssaps and CPP) within 60 days, in accordance with European directive. Its performance in early phases, oncology/hematology and vaccines/anti-infectious contribute to the attractiveness of France in international clinical research.
authors.affiliation: Les Entreprises du Médicament (Leem), Paris, France.
authors.forename: Catherine
authors.initials: C
authors.lastname: Lassale
authors.affiliation: Les Entreprises du Médicament (Leem), Paris, France. Electronic address: csibenaler@leem.org.
authors.forename: Claire
authors.initials: C
authors.lastname: Sibenaler
authors.affiliation: Merck Sharpe et Dohme Chibret, Paris, France.
authors.forename: Jehan-Michel
authors.initials: JM
authors.lastname: Béhier
authors.affiliation: Pfizer, Paris, France.
authors.forename: Yannick
authors.initials: Y
authors.lastname: Plétan
authors.affiliation: Glaxo SmithKline, Marly-le-Roi, France.
authors.forename: Soizic
authors.initials: S
authors.lastname: Courcier
keywords: France; competitiveness; compétitivité; entreprises du médicament; international clinical research; pharmaceutical companies; recherche clinique internationale